Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

Proteomic Profiling of Burkholderia thailandensis During Host Infection Using Bio-Orthogonal Noncanonical Amino Acid Tagging (BONCAT).

Franco M, D'haeseleer PM, Branda SS, Liou MJ, Haider Y, Segelke BW, El-Etr SH.

Front Cell Infect Microbiol. 2018 Oct 23;8:370. doi: 10.3389/fcimb.2018.00370. eCollection 2018.

2.

Structure and function of REP34 implicates carboxypeptidase activity in Francisella tularensis host cell invasion.

Feld GK, El-Etr S, Corzett MH, Hunter MS, Belhocine K, Monack DM, Frank M, Segelke BW, Rasley A.

J Biol Chem. 2014 Oct 31;289(44):30668-79. doi: 10.1074/jbc.M114.599381. Epub 2014 Sep 17.

3.

Practical applications of structural genomics technologies for mutagen research.

Zemla A, Segelke BW.

Mutat Res. 2011 Jun 17;722(2):165-70. doi: 10.1016/j.mrgentox.2010.12.006. Epub 2010 Dec 21.

PMID:
21182983
4.

Isolation, characterization, and stability of discretely-sized nanolipoprotein particles assembled with apolipophorin-III.

Fischer NO, Blanchette CD, Segelke BW, Corzett M, Chromy BA, Kuhn EA, Bench G, Hoeprich PD.

PLoS One. 2010 Jul 19;5(7):e11643. doi: 10.1371/journal.pone.0011643.

5.

Structure of Rv1848 (UreA), the Mycobacterium tuberculosis urease gamma subunit.

Habel JE, Bursey EH, Rho BS, Kim CY, Segelke BW, Rupp B, Park MS, Terwilliger TC, Hung LW.

Acta Crystallogr Sect F Struct Biol Cryst Commun. 2010 Jul 1;66(Pt 7):781-6. doi: 10.1107/S1744309110019536. Epub 2010 Jun 23.

6.

Amino acid and structural variability of Yersinia pestis LcrV protein.

Anisimov AP, Dentovskaya SV, Panfertsev EA, Svetoch TE, Kopylov PKh, Segelke BW, Zemla A, Telepnev MV, Motin VL.

Infect Genet Evol. 2010 Jan;10(1):137-45. doi: 10.1016/j.meegid.2009.10.003. Epub 2009 Oct 14.

7.

Characterization and purification of polydisperse reconstituted lipoproteins and nanolipoprotein particles.

Blanchette CD, Segelke BW, Fischer N, Corzett MH, Kuhn EA, Cappuccio JA, Benner WH, Coleman MA, Chromy BA, Bench G, Hoeprich PD, Sulchek TA.

Int J Mol Sci. 2009 Jul 2;10(7):2958-71. doi: 10.3390/ijms10072958.

8.

Immobilization of His-tagged proteins on nickel-chelating nanolipoprotein particles.

Fischer NO, Blanchette CD, Chromy BA, Kuhn EA, Segelke BW, Corzett M, Bench G, Mason PW, Hoeprich PD.

Bioconjug Chem. 2009 Mar 18;20(3):460-5. doi: 10.1021/bc8003155.

PMID:
19239247
9.

Atomic force microscopy differentiates discrete size distributions between membrane protein containing and empty nanolipoprotein particles.

Blanchette CD, Cappuccio JA, Kuhn EA, Segelke BW, Benner WH, Chromy BA, Coleman MA, Bench G, Hoeprich PD, Sulchek TA.

Biochim Biophys Acta. 2009 Mar;1788(3):724-31. doi: 10.1016/j.bbamem.2008.11.019. Epub 2008 Dec 8.

10.

Cell-free expression for nanolipoprotein particles: building a high-throughput membrane protein solubility platform.

Cappuccio JA, Hinz AK, Kuhn EA, Fletcher JE, Arroyo ES, Henderson PT, Blanchette CD, Walsworth VL, Corzett MH, Law RJ, Pesavento JB, Segelke BW, Sulchek TA, Chromy BA, Katzen F, Peterson T, Bench G, Kudlicki W, Hoeprich PD Jr, Coleman MA.

Methods Mol Biol. 2009;498:273-96. doi: 10.1007/978-1-59745-196-3_18.

PMID:
18988032
11.

Cell-free co-expression of functional membrane proteins and apolipoprotein, forming soluble nanolipoprotein particles.

Cappuccio JA, Blanchette CD, Sulchek TA, Arroyo ES, Kralj JM, Hinz AK, Kuhn EA, Chromy BA, Segelke BW, Rothschild KJ, Fletcher JE, Katzen F, Peterson TC, Kudlicki WA, Bench G, Hoeprich PD, Coleman MA.

Mol Cell Proteomics. 2008 Nov;7(11):2246-53. doi: 10.1074/mcp.M800191-MCP200. Epub 2008 Jul 4.

12.

Efficient macromolecular crystallization using microfluidics and randomized design of screening reagents.

May AP, Segelke BW.

Methods Mol Biol. 2008;426:387-402. doi: 10.1007/978-1-60327-058-8_25.

PMID:
18542878
13.

Quantifying size distributions of nanolipoprotein particles with single-particle analysis and molecular dynamic simulations.

Blanchette CD, Law R, Benner WH, Pesavento JB, Cappuccio JA, Walsworth V, Kuhn EA, Corzett M, Chromy BA, Segelke BW, Coleman MA, Bench G, Hoeprich PD, Sulchek TA.

J Lipid Res. 2008 Jul;49(7):1420-30. doi: 10.1194/jlr.M700586-JLR200. Epub 2008 Apr 9.

14.

High throughput crystallography of TB drug targets.

Murillo AC, Li HY, Alber T, Baker EN, Berger JM, Cherney LT, Cherney MM, Cho YS, Eisenberg D, Garen CR, Goulding CW, Hung LW, Ioerger TR, Jacobs WR, James MN, Kim C, Krieger I, Lott JS, Sankaranarayanan R, Segelke BW, Terwilliger TC, Wang F, Wang S, Sacchettini JC.

Infect Disord Drug Targets. 2007 Jun;7(2):127-39. Review.

PMID:
17970224
15.

Different apolipoproteins impact nanolipoprotein particle formation.

Chromy BA, Arroyo E, Blanchette CD, Bench G, Benner H, Cappuccio JA, Coleman MA, Henderson PT, Hinz AK, Kuhn EA, Pesavento JB, Segelke BW, Sulchek TA, Tarasow T, Walsworth VL, Hoeprich PD.

J Am Chem Soc. 2007 Nov 21;129(46):14348-54. Epub 2007 Oct 27.

PMID:
17963384
16.

Crystal structure of a putative pyridoxine 5'-phosphate oxidase (Rv2607) from Mycobacterium tuberculosis.

Pédelacq JD, Rho BS, Kim CY, Waldo GS, Lekin TP, Segelke BW, Rupp B, Hung LW, Kim SI, Terwilliger TC.

Proteins. 2006 Mar 15;62(3):563-9.

PMID:
16374842
17.

Structure of pyrR (Rv1379) from Mycobacterium tuberculosis: a persistence gene and protein drug target.

Kantardjieff KA, Vasquez C, Castro P, Warfel NM, Rho BS, Lekin T, Kim CY, Segelke BW, Terwilliger TC, Rupp B.

Acta Crystallogr D Biol Crystallogr. 2005 Apr;61(Pt 4):355-64. Epub 2005 Mar 24.

PMID:
15805589
18.

Crystal Structure of AhpE from Mycobacterium tuberculosis, a 1-Cys peroxiredoxin.

Li S, Peterson NA, Kim MY, Kim CY, Hung LW, Yu M, Lekin T, Segelke BW, Lott JS, Baker EN.

J Mol Biol. 2005 Mar 4;346(4):1035-46. Epub 2005 Jan 25.

PMID:
15701515
19.

High-throughput, fluorescence-based screening for soluble protein expression.

Coleman MA, Lao VH, Segelke BW, Beernink PT.

J Proteome Res. 2004 Sep-Oct;3(5):1024-32.

PMID:
15473692
20.

Laboratory scale structural genomics.

Segelke BW, Schafer J, Coleman MA, Lekin TP, Toppani D, Skowronek KJ, Kantardjieff KA, Rupp B.

J Struct Funct Genomics. 2004;5(1-2):147-57.

PMID:
15263853
21.

Mycobacterium tuberculosis RmlC epimerase (Rv3465): a promising drug-target structure in the rhamnose pathway.

Kantardjieff KA, Kim CY, Naranjo C, Waldo GS, Lekin T, Segelke BW, Zemla A, Park MS, Terwilliger TC, Rupp B.

Acta Crystallogr D Biol Crystallogr. 2004 May;60(Pt 5):895-902. Epub 2004 Apr 21.

PMID:
15103135
22.

The high-speed Hydra-Plus-One system for automated high-throughput protein crystallography.

Krupka HI, Rupp B, Segelke BW, Lekin TP, Wright D, Wu HC, Todd P, Azarani A.

Acta Crystallogr D Biol Crystallogr. 2002 Oct;58(Pt 10 Pt 1):1523-6. Epub 2002 Sep 26.

PMID:
12351853
23.

The TB structural genomics consortium crystallization facility: towards automation from protein to electron density.

Rupp B, Segelke BW, Krupka HI, Lekin T, Schäfer J, Zemla A, Toppani D, Snell G, Earnest T.

Acta Crystallogr D Biol Crystallogr. 2002 Oct;58(Pt 10 Pt 1):1514-8. Epub 2002 Sep 26.

PMID:
12351851
24.

Concanavalin A in a dimeric crystal form: revisiting structural accuracy and molecular flexibility.

Kantardjieff KA, Höchtl P, Segelke BW, Tao FM, Rupp B.

Acta Crystallogr D Biol Crystallogr. 2002 May;58(Pt 5):735-43. Epub 2002 Apr 26.

PMID:
11976483
25.

Structural basis for abrogated binding between staphylococcal enterotoxin A superantigen vaccine and MHC-IIalpha.

Krupka HI, Segelke BW, Ulrich RG, Ringhofer S, Knapp M, Rupp B.

Protein Sci. 2002 Mar;11(3):642-51.

26.

Two divalent metal ions in the active site of a new crystal form of human apurinic/apyrimidinic endonuclease, Ape1: implications for the catalytic mechanism.

Beernink PT, Segelke BW, Hadi MZ, Erzberger JP, Wilson DM 3rd, Rupp B.

J Mol Biol. 2001 Apr 6;307(4):1023-34.

PMID:
11286553
27.

Interaction of the N-terminal domain of apolipoprotein E4 with heparin.

Dong J, Peters-Libeu CA, Weisgraber KH, Segelke BW, Rupp B, Capila I, Hernáiz MJ, LeBrun LA, Linhardt RJ.

Biochemistry. 2001 Mar 6;40(9):2826-34.

PMID:
11258893
28.

Conformational flexibility in the apolipoprotein E amino-terminal domain structure determined from three new crystal forms: implications for lipid binding.

Segelke BW, Forstner M, Knapp M, Trakhanov SD, Parkin S, Newhouse YM, Bellamy HD, Weisgraber KH, Rupp B.

Protein Sci. 2000 May;9(5):886-97.

29.

The CD1 family of lipid antigen-presenting molecules.

Porcelli SA, Segelke BW, Sugita M, Wilson IA, Brenner MB.

Immunol Today. 1998 Aug;19(8):362-8. Review. No abstract available.

PMID:
9709504
30.

Structures of two novel crystal forms of Naja naja naja phospholipase A2 lacking Ca2+ reveal trimeric packing.

Segelke BW, Nguyen D, Chee R, Xuong NH, Dennis EA.

J Mol Biol. 1998 May 29;279(1):223-32.

PMID:
9636712
31.

Crystal structure of mouse CD1: An MHC-like fold with a large hydrophobic binding groove.

Zeng Z, Castaño AR, Segelke BW, Stura EA, Peterson PA, Wilson IA.

Science. 1997 Jul 18;277(5324):339-45.

32.

Interaction of phospholipase A2 with thioether amide containing phospholipid analogues.

Plesniak LA, Boegeman SC, Segelke BW, Dennis EA.

Biochemistry. 1993 May 18;32(19):5009-16.

PMID:
8494876

Supplemental Content

Loading ...
Support Center